SCHEMBL30809183

SCHEMBL30809183

O=C1Cc2cnc(Cl)cc2N1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 4/20 0.53
CMA1 P23946 2/20 0.53
EIF2AK2 P19525 1/20 0.43
BCL6 P41182 1/20 0.42
PDK2 Q15119 1/20 0.41
KDM1A O60341 1/20 0.41
PGR P06401 1/20 0.41
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
PLK1 P53350 4/20 0.40
KDR P35968 4/20 0.39
CHEK1 O14757 1/20 0.39
AURKA O14965 1/20 0.39
DAPK3 O43293 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
ABL1 P00519 1/20 0.39
NTRK1 P04629 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL659822 1.00 AHR (0.53) AHRCMA1EIF2AK2BCL6PDK2
SCHEMBL29435574 0.85 AHR (0.53) AHRCMA1EIF2AK2BCL6PDK2
SCHEMBL8653630 0.85 AHR (0.53) AHRCMA1EIF2AK2BCL6PDK2
SCHEMBL5372273 0.84 CA9 (0.46) AHRCMA1PDE3BPDE3ACYP1A2
SCHEMBL13650417 0.78 AHR (0.44) AHRCMA1EIF2AK2BCL6PDK2
SCHEMBL19153946 0.78 AHR (0.44) AHRCMA1EIF2AK2PDK2KDM1A
SCHEMBL18238729 0.77 AHR (0.41) AHRCMA1EIF2AK2PDK2KDM1A
SCHEMBL23302034 0.75 MB (0.49) AHRCMA1PDE3BPDE3ACYP11B1
SCHEMBL30699001 0.75 TDP2 (0.51) AHRCMA1
SCHEMBL22885217 0.75 TDP2 (0.51) AHRCMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4543544-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-04-30 EP disclosed
CN-119866338-A Tyrosine kinase 2 inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-22 CN disclosed
US-20240246989-A1 DISPIROPYRROLIDINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-07-25 US disclosed
WO-2023250064-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246989-A1 DISPIROPYRROLIDINE DERIVATIVES MDM2, TP53, TP53BP1 AHR 2432/4885CMA1 2799/4885EIF2AK2 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.